Bivalirudin and thrombolytic therapy: a novel successful treatment of severe aortic arch thrombosis in a term neonate

BMJ Case Rep. 2021 Jan 18;14(1):e239535. doi: 10.1136/bcr-2020-239535.

Abstract

An early-term infant with uncomplicated perinatal history was found to have a large thrombus in the aortic arch after he failed regular newborn critical congenital heart defect screen. He responded well to bivalirudin thrombolytic and tissue-plasminogen activator (tPA) combination therapy, with a significant resolution of the thrombus. The infant tolerated hospital admission well with no significant complications. He was discharged home on daily aspirin at 2 weeks of life. To our knowledge, the combination therapy approach with bivalirudin and tPA is the first one reported in the literature in the neonatal age group.

Keywords: cardiovascular system; haematology (drugs and medicines); neonatal intensive care; paediatrics (drugs and medicines); routine care of the full-time infant.

Publication types

  • Case Reports

MeSH terms

  • Age Factors
  • Antithrombins / therapeutic use*
  • Aorta, Thoracic*
  • Aortic Diseases / diagnostic imaging
  • Aortic Diseases / drug therapy*
  • Hirudins
  • Humans
  • Infant, Newborn
  • Male
  • Peptide Fragments / therapeutic use*
  • Recombinant Proteins / therapeutic use
  • Thrombolytic Therapy*
  • Thrombosis / diagnostic imaging
  • Thrombosis / drug therapy*

Substances

  • Antithrombins
  • Hirudins
  • Peptide Fragments
  • Recombinant Proteins
  • bivalirudin